Apilimod
Kinase inhibitor: PIKfyve
- Applications:Blocks entry of SARS-CoV-2 into cells by disrupting cellular trafficking
Biochemicals & reagents
541550-19-0
STA-5326
1) Wada, et al. (2007), Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL23 inhibitor; Blood 109 1156 2) Cai et al. (2013), PIKfyve, a class III PI-kinase, is the target of the small molecule IL12/23 inhibitor apilimod and a new player in toll-like receptor signaling; Chem. Biol. 20 912 3) Gayle et al. (2016), Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma; Blood 129 1768 4) Kang et al. (2020), Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2; Proc. Natl. Acad. Sci. USA. 117 20803
418.5
-20°C (des.)
Apilimod is a potent (IC50 = 10 nM IFN-g/LPS-stimulated human PMBC’s; IC50 = 1 nM in IFN-g/SAC-stimulated human PMBC’s) IL-12/IL-23 inhibitor downregulating both at the transcriptional level. Suppresses Th1 but not Th2 immune response.1 Inhibition was also observed in human monocytes, monocyte-derived dendritic cells, and THP-1 cells. Apilimod’s mechanism of action is mediation of TLR signaling via inhibition of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve; IC50 = 14 nM).2 It displayed selective cytotoxic activity in B-cell non-Hodgkin lymphoma compared with normal cells.3 Apilimod prevented infection of VSV-ZEBOV and VSV-SARS-CoV-2 (IC50 = 50 nM) as well as SARS-CoV-2 strain 2019-nCoVB/USA-1WA/2020.4